Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Alexion PharmaceuticalsShiseidoAstellas PharmaBeiGeneTakeda Pharmaceutical
SymbolNASDAQ:ALXNOTCMKTS:SSDOYOTCMKTS:ALPMYNASDAQ:BGNEOTCMKTS:TKPYY
Price Information
Current Price$155.01$68.32$14.92$308.27$17.25
52 Week RangeHoldHoldBuyHoldN/A
MarketRank™
Overall Score1.70.91.71.31.0
Analysis Score1.20.00.02.20.0
Community Score3.12.22.72.82.7
Dividend Score0.01.72.50.00.8
Ownership Score1.70.00.00.80.0
Earnings & Valuation Score2.50.63.10.61.3
Analyst Ratings
Consensus RecommendationHoldHoldBuyHoldN/A
Consensus Price Target$153.86N/AN/A$319.38N/A
% Upside from Price Target-0.74% downsideN/AN/A3.60% upsideN/A
Trade Information
Market Cap$34.08 billion$27.29 billion$27.78 billion$28.23 billion$26.95 billion
Beta1.330.330.630.910.42
Average Volume2,663,33419,61075,832314,904979,605
Sales & Book Value
Annual Revenue$4.99 billion$10.38 billion$11.97 billion$428.21 million$15.99 billion
Price / Sales6.832.632.3265.921.69
Cashflow$11.58 per share$3.28 per share$1.20 per shareN/A$2.29 per share
Price / Cash13.3920.8512.47N/A7.52
Book Value$50.91 per share$11.93 per share$6.28 per share$15.87 per share$11.62 per share
Price / Book3.045.732.3819.421.48
Profitability
Net Income$2.40 billion$676.77 million$1.80 billion$-948,630,000.00$1.68 billion
EPS$9.74$1.72$0.96($15.80)N/A
Trailing P/E Ratio36.22N/A21.62N/A12.11
Forward P/E Ratio13.2173.469.82N/A
P/E Growth0.75N/AN/AN/AN/A
Net Margins16.32%-1.33%11.03%-569.22%7.84%
Return on Equity (ROE)23.16%0.95%13.24%-56.81%11.35%
Return on Assets (ROA)14.76%0.40%7.89%-39.93%5.57%
Dividend
Annual PayoutN/A$0.27$0.29N/A$0.58
Dividend YieldN/A0.40%1.94%N/A3.36%
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/A15.70%30.21%N/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.22%0.25%N/A0.04%0.48%
Current Ratio3.81%1.11%1.23%7.69%1.42%
Quick Ratio3.26%0.68%0.99%7.64%1.12%
Ownership Information
Institutional Ownership Percentage87.27%0.14%0.18%60.65%0.19%
Insider Ownership Percentage4.03%N/AN/A9.00%N/A
Miscellaneous
Employees3,83740,00015,8835,300N/A
Shares Outstanding219.85 million399.39 million1.86 billion91.57 million1.56 billion
Next Earnings Date5/5/2021 (Estimated)5/11/2021 (Estimated)5/13/2021 (Estimated)5/10/2021 (Estimated)N/A
OptionableOptionableNot OptionableNot OptionableOptionableNot Optionable
SourceHeadline
Takeda Pharmaceutical (OTCMKTS:TKPYY)  Shares Down 0.3% Takeda Pharmaceutical (OTCMKTS:TKPYY) Shares Down 0.3%
americanbankingnews.com - March 27 at 12:26 AM
Takeda Files Japan Marketing Application For Darvadstrocel In Crohns DiseaseTakeda Files Japan Marketing Application For Darvadstrocel In Crohn's Disease
feeds.benzinga.com - February 10 at 6:47 AM
Prime Therapeutics and Takeda agree to outcomes-based arrangement for Hemophilia A treatment ADVATE® [Antihemophilic Factor (Recombinant)]Prime Therapeutics and Takeda agree to outcomes-based arrangement for Hemophilia A treatment ADVATE® [Antihemophilic Factor (Recombinant)]
benzinga.com - December 16 at 9:42 AM
Takeda preparing to sell Japan consumer health unit to Blackstone -KyodoTakeda preparing to sell Japan consumer health unit to Blackstone -Kyodo
financialpost.com - August 18 at 10:51 PM
Takeda Pharmaceutical Company Limited -- Moodys adds details on Takedas rated senior unsecured notesTakeda Pharmaceutical Company Limited -- Moody's adds details on Takeda's rated senior unsecured notes
finance.yahoo.com - June 30 at 7:12 AM
Why Translate Bios Stock Is Trading Lower TodayWhy Translate Bio's Stock Is Trading Lower Today
feeds.benzinga.com - June 25 at 11:21 AM
Takeda Issues Update From AHEAD Study With ADVATE In Hemophilia A PatientsTakeda Issues Update From AHEAD Study With ADVATE In Hemophilia A Patients
www.nasdaq.com - June 15 at 8:33 AM
Takeda says coronavirus treatment trial using recovered patients’ blood could start in JulyTakeda says coronavirus treatment trial using recovered patients’ blood could start in July
business.financialpost.com - May 13 at 8:19 PM
Takeda says coronavirus treatment trial using recovered patients blood could start in JulyTakeda says coronavirus treatment trial using recovered patients' blood could start in July
feeds.reuters.com - May 13 at 8:02 PM
Japan’s Takeda sells $670 mln of Europe OTC assets to pare debtJapan’s Takeda sells $670 mln of Europe OTC assets to pare debt
business.financialpost.com - April 24 at 5:01 AM
Japan’s Takeda plans to sell consumer health unit for around $3.7 bln – NikkeiJapan’s Takeda plans to sell consumer health unit for around $3.7 bln – Nikkei
business.financialpost.com - April 24 at 12:38 AM
Takeda Pharma TOURMALINE-MM2 Phase 3 Study Meets Primary EndpointTakeda Pharma TOURMALINE-MM2 Phase 3 Study Meets Primary Endpoint
markets.businessinsider.com - March 10 at 8:57 AM
Japans Takeda forecasts surprise full-year operating profitJapan's Takeda forecasts surprise full-year operating profit
feeds.reuters.com - February 4 at 6:56 AM
Nidda Healthcare Holding GMBH -- Moodys affirms Niddas B3 CFR following M&A transactions; stable outlookNidda Healthcare Holding GMBH -- Moody's affirms Nidda's B3 CFR following M&A transactions; stable outlook
finance.yahoo.com - November 11 at 5:07 PM
Takeda To Sell Select Products To STADA For $660 Mln; Stock UpTakeda To Sell Select Products To STADA For $660 Mln; Stock Up
www.nasdaq.com - November 5 at 7:07 AM
Takeda scraps late-stage amyloidosis studyTakeda scraps late-stage amyloidosis study
feeds.reuters.com - June 5 at 5:53 PM
Takeda FY18 Profit Down, Revenues ClimbTakeda FY18 Profit Down, Revenues Climb
markets.businessinsider.com - May 14 at 11:35 AM
Takeda To Sell Dry Eye Drug, Surgical Patch To Novartis, J&J For Up To $5.7 BlnTakeda To Sell Dry Eye Drug, Surgical Patch To Novartis, J&J For Up To $5.7 Bln
markets.businessinsider.com - May 9 at 11:09 AM
Takeda sells dry eye drug to Novartis to help cut debtTakeda sells dry eye drug to Novartis to help cut debt
feeds.reuters.com - May 8 at 11:13 PM
Shire Acq Inv Ireland Designated Activity Co -- Moodys announces completion of a periodic review of ratings of Shire Acq Inv Ireland Designated Activity CoShire Acq Inv Ireland Designated Activity Co -- Moody's announces completion of a periodic review of ratings of Shire Acq Inv Ireland Designated Activity Co
finance.yahoo.com - February 15 at 4:18 PM
Takeda Reportedly Considers Sale Of $3 Billion In Emerging-Market AssetsTakeda Reportedly Considers Sale Of $3 Billion In Emerging-Market Assets
www.nasdaq.com - January 22 at 10:44 AM
This pharmaceutical company is like four biotechs in one,...This pharmaceutical company is like four biotechs in one,...
finance.yahoo.com - January 15 at 4:18 PM
Takeda Pharmaceutical CEO Talks Big Pharma TrendsTakeda Pharmaceutical CEO Talks Big Pharma Trends
finance.yahoo.com - January 15 at 4:18 PM
Japan Olympics boss suspected of campaign briberyJapan Olympics boss suspected of campaign bribery
news.yahoo.com - January 11 at 4:08 PM
Olympics-IOC opens ethics file on Takeda, to meet FridayOlympics-IOC opens ethics file on Takeda, to meet Friday
finance.yahoo.com - January 11 at 11:04 AM
DateCompanyBrokerageAction
3/29/2021Alexion PharmaceuticalsSVB LeerinkReiterated Rating
2/4/2021Alexion PharmaceuticalsPiper SandlerDowngrade
1/8/2021Alexion PharmaceuticalsRaymond JamesDowngrade
12/16/2020Alexion PharmaceuticalsTruistDowngrade
12/15/2020Alexion PharmaceuticalsSmith Barney CitigroupDowngrade
12/15/2020Alexion PharmaceuticalsRoth CapitalBoost Price Target
12/15/2020Alexion PharmaceuticalsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellReiterated Rating
12/14/2020Alexion PharmaceuticalsRobert W. BairdDowngrade
12/14/2020Alexion PharmaceuticalsWedbushDowngrade
12/14/2020Alexion PharmaceuticalsRoyal Bank of CanadaBoost Price Target
12/14/2020Alexion PharmaceuticalsBMO Capital MarketsDowngrade
12/14/2020Alexion PharmaceuticalsCredit Suisse GroupDowngrade
11/19/2020Alexion PharmaceuticalsSanford C. BernsteinInitiated Coverage
10/30/2020Alexion PharmaceuticalsSvb LeerinkLower Price Target
10/30/2020Alexion PharmaceuticalsMorgan StanleyLower Price Target
10/28/2020Alexion PharmaceuticalsUBS GroupInitiated Coverage
11/11/2020ShiseidoDaiwa Capital MarketsUpgrade
9/30/2020ShiseidoJefferies Financial GroupUpgrade
9/4/2020ShiseidoThe Goldman Sachs GroupDowngrade
8/7/2020ShiseidoCLSADowngrade
6/24/2020ShiseidoJPMorgan Chase & Co.Upgrade
9/13/2018Astellas PharmaDeutsche Bank AktiengesellschaftDowngrade
3/16/2021BeiGeneHSBCBoost Price Target
3/8/2021BeiGeneChina Renaissance SecuritiesInitiated Coverage
2/25/2021BeiGeneCowenBoost Price Target
12/8/2020BeiGeneLADENBURG THALM/SH SHUpgrade
11/6/2020BeiGeneMaxim GroupDowngrade
3/13/2020BeiGeneMacquarieUpgrade
(Data available from 4/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.